X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Novartis with ACTAVIS INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs ACTAVIS (US) - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 NOVARTIS   ACTAVIS
EQUITY SHARE DATA
    NOVARTIS
Mar-16
ACTAVIS
Dec-14
NOVARTIS/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs98217,702-   
Low Rs55610,798-   
Sales per share (Unadj.) Rs252.93,187.6-  
Earnings per share (Unadj.) Rs62.1-397.8-  
Cash flow per share (Unadj.) Rs63.3292.5-  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.30-  
Book value per share (Unadj.) Rs363.66,913.9-  
Shares outstanding (eoy) m31.96265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.04.5 68.0%   
Avg P/E ratio x12.4-35.8 -34.5%  
P/CF ratio (eoy) x12.248.7 24.9%  
Price / Book Value ratio x2.12.1 102.6%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m24,5803,789,034 0.6%   
No. of employees `0000.821.6 3.5%   
Total wages/salary Rs m1,8010-   
Avg. sales/employee Rs Th10,748.939,240.4 27.4%   
Avg. wages/employee Rs Th2,395.20-   
Avg. net profit/employee Rs Th2,641.1-4,896.8 -53.9%   
INCOME DATA
Net Sales Rs m8,083847,593 1.0%  
Other income Rs m829-2,115 -39.2%   
Total revenues Rs m8,913845,478 1.1%   
Gross profit Rs m234108,885 0.2%  
Depreciation Rs m37183,535 0.0%   
Interest Rs m226,735 0.0%   
Profit before tax Rs m1,025-103,500 -1.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m170-   
Extraordinary Inc (Exp) Rs m1,696-7,592 -22.3%   
Tax Rs m752-5,321 -14.1%   
Profit after tax Rs m1,986-105,771 -1.9%  
Gross profit margin %2.912.8 22.6%  
Effective tax rate %73.45.1 1,426.9%   
Net profit margin %24.6-12.5 -196.9%  
BALANCE SHEET DATA
Current assets Rs m12,678446,573 2.8%   
Current liabilities Rs m2,433325,683 0.7%   
Net working cap to sales %126.714.3 888.6%  
Current ratio x5.21.4 380.0%  
Inventory Days Days3358 56.4%  
Debtors Days Days2266 33.9%  
Net fixed assets Rs m69103,500 0.1%   
Share capital Rs m1600-   
"Free" reserves Rs m11,4600-   
Net worth Rs m11,6211,838,399 0.6%   
Long term debt Rs m0963,357 0.0%   
Total assets Rs m14,4003,369,180 0.4%  
Interest coverage x570.5-2.9 -19,868.6%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x0.60.3 223.1%   
Return on assets %13.8-2.3 -588.5%  
Return on equity %17.1-5.8 -297.0%  
Return on capital %23.6-3.0 -783.0%  
Exports to sales %0.70-   
Imports to sales %18.60-   
Net fx Rs m-1,6350-   
CASH FLOW
From Operations Rs m2,531145,548 1.7%  
From Investments Rs m-8,270-348,498 2.4%  
From Financial Activity Rs m-386195,806 -0.2%  
Net Cashflow Rs m-6,125-7,144 85.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 64.89 Rs / USD

Compare NOVARTIS With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare NOVARTIS With: ELDER PHARMA  ALEMBIC PHARMA  UNICHEM LAB  CIPLA  GSK PHARMA  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Feb 23, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS